Table 2. Disease-free survival rates for the training and validation series, disease-specific survival rates (maximum) for training series patients (stage 2 and 3) and validation series patients.

Series	Clinical Stage	Risk group	Percent of series	5-year DFS (%)	Log-rank P-value	5-year DSS	Log rank P-value
Training	2	Low	31	89	0.0002	100%	0.010
		High	35	63		70%
	3	Low	16	87	0.0016	96%	0.0017
		High	18	43		61%
Validation	2	Low	32	100	0.031
		High	23	73		NA
	3	Low	27	75	0.057
		High	18	26

Abbreviation: NA=not available.